9999999997-19-004114.txt : 20190509 9999999997-19-004114.hdr.sgml : 20190509 20190509095909 ACCESSION NUMBER: 9999999997-19-004114 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190509 DATE AS OF CHANGE: 20190509 ACTION DATE: 20190509 RECEIVED DATE: 20190509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 19809152 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 CT ORDER 1 filename1.pdf begin 644 filename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end